Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Stattin Pär) "

Sökning: WFRF:(Stattin Pär)

Sortera/gruppera träfflistan
  • Bonn, Stephanie E, et al. (författare)
  • Body mass index and weight change in men with prostate cancer: progression and mortality.
  • 2014
  • Ingår i: Cancer causes & control : CCC. - 1573-7225. ; 25:8, s. 933-94
  • Tidskriftsartikel (refereegranskat)abstract
    • Body mass index (BMI) is a modifiable lifestyle factor that has been associated with an increased risk of fatal prostate cancer and biochemical recurrence. The main purpose of the present study was to investigate the association between the exposure BMI at the time of a prostate cancer diagnosis and weight change after diagnosis, and the outcomes of prostate cancer progression and mortality in a large cohort study.
  • Bosco, Cecilia, et al. (författare)
  • Prostate Cancer Radiation Therapy and Risk of Thromboembolic Events
  • 2017
  • Ingår i: International Journal of Radiation Oncology Biology Physics. - Elsevier. - 0360-3016. ; 97:5, s. 1026-1031
  • Tidskriftsartikel (refereegranskat)abstract
    • Purpose To investigate the risk of thromboembolic disease (TED) after radiation therapy (RT) with curative intent for prostate cancer (PCa). Patients and Methods We identified all men who received RT as curative treatment (n=9410) and grouped according to external beam RT (EBRT) or brachytherapy (BT). By comparing with an age- and county-matched comparison cohort of PCa-free men (n=46,826), we investigated risk of TED after RT using Cox proportional hazard regression models. The model was adjusted for tumor characteristics, demographics, comorbidities, PCa treatments, and known risk factors of TED, such as recent surgery and disease progression. Results Between 2006 and 2013, 6232 men with PCa received EBRT, and 3178 underwent BT. A statistically significant association was found between EBRT and BT and risk of pulmonary embolism in the crude analysis. However, upon adjusting for known TED risk factors these associations disappeared. No significant associations were found between BT or EBRT and deep venous thrombosis. Conclusion Curative RT for prostate cancer using contemporary methodologies was not associated with an increased risk of TED.
  • Bratt, Ola, et al. (författare)
  • Effects of Prostate-Specific Antigen Testing on Familial Prostate Cancer Risk Estimates.
  • 2010
  • Ingår i: Journal of the National Cancer Institute. - Oxford University Press. - 1460-2105. ; 102, s. 1336-1343
  • Tidskriftsartikel (refereegranskat)abstract
    • Background Family history is a strong risk factor for prostate cancer. The aim of this study was to investigate whether increased diagnostic activity is related to the incidence of prostate cancer among brothers of men with prostate cancer. Methods Data were from the nationwide population-based Prostate Cancer Database Sweden (PCBaSe Sweden), which includes data from the National Prostate Cancer Register, the Swedish Cancer Register, the Register of the Total Population, the Multi-Generation Register, and the Census database. We investigated the relationship of tumor characteristics, time from diagnosis of the index patient (ie, prostate cancer patients in the National Prostate Cancer Register for whom at least one brother and their father could be identified), calendar period, geographic factors, and socioeconomic status to standardized incidence ratios (SIRs) for prostate cancer among 22 511 brothers of 13 975 index patients in PCBaSe Sweden. Results Brothers of index patients with prostate cancer were at increased risk for a diagnosis of prostate cancer (SIR = 3.1, 95% confidence interval [CI] = 2.9 to 3.3). Risk was higher for T1c tumors (SIR = 3.4, 95% CI = 3.2 to 3.8) than for metastatic tumors (SIR = 2.0, 95% CI = 1.5 to 2.6), and risk of T1c tumors was especially high during the first year after the diagnosis of the index patient (SIR = 4.3, 95% CI = 3.8 to 4.9), compared with the following years (SIR range = 2.8-3.3), and for brothers of index patients who had a higher socioeconomic status (SIR = 4.2, 95% CI = 3.7 to 4.7), compared with brothers of index patients with lower socioeconomic status (SIR = 2.8, 95% CI = 2.4 to 3.2). Conclusions Increased diagnostic activity among men with a family history of prostate cancer appears to contribute to their increased risk of prostate cancer and to lead to detection bias in epidemiological and genetic studies of familial prostate cancer.
  • Bratt, Ola, et al. (författare)
  • Family History and Probability of Prostate Cancer, Differentiated by Risk Category : : A Nationwide Population-Based Study
  • 2016
  • Ingår i: Journal of the National Cancer Institute. - Oxford University Press. - 0027-8874. ; 108:10
  • Tidskriftsartikel (refereegranskat)abstract
    • Background: Familial prostate cancer risk estimates are inflated by clinically insignificant low-risk cancer, diagnosed after prostate-specific antigen testing. We provide age-specific probabilities of non-low- and high-risk prostate cancer. Methods: Fifty-one thousand, eight hundred ninety-seven brothers of 32 807 men with prostate cancer were identified in Prostate Cancer data Base Sweden (PCBaSe). Nelson-Aalen estimates with 95% confidence intervals (CIs) were calculated for cumulative, family history-stratified probabilities of any, non-low- (any of Gleason score ≥ 7, prostate-specific antigen [PSA] ≥ 10 ng/mL, T3-4, N1, and/or M1) and high-risk prostate cancer (Gleason score ≥ 8 and/or T3-4 and/or PSA ≥ 20 ng/mL and/or N1 and/or M1). Results: The population probability of any prostate cancer was 4.8% (95% CI = 4.8% to 4.9%) at age 65 years and 12.9% (95% CI = 12.8% to 12.9%) at age 75 years, of non-low-risk prostate cancer 2.8% (95% CI = 2.7% to 2.8%) at age 65 years and 8.9% (95% CI = 8.8% to 8.9%) at age 75 years, and of high-risk prostate cancer 1.4% (95% CI = 1.3% to 1.4%) at age 65 years and 5.2% (95% CI = 5.1% to 5.2%) at age 75 years. For men with one affected brother, probabilities of any prostate cancer were 14.9% (95% CI = 14.1% to 15.8%) at age 65 years and 30.3% (95% CI = 29.3% to 31.3%) at age 75 years, of non-low-risk prostate cancer 7.3% (95% CI = 6.7% to 7.9%) at age 65 years and 18.8% (95% CI = 17.9% to 19.6%) at age 75 years, and of high-risk prostate cancer 3.0% (95% CI = 2.6% to 3.4%) at age 65 years and 8.9% (95% CI = 8.2% to 9.5%) at age 75 years. Probabilities were higher for men with a stronger family history. For example, men with two affected brothers had a 13.6% (95% CI = 9.9% to 17.6 %) probability of high-risk cancer at age 75 years. Conclusions: The age-specific probabilities of non-low- and high-risk cancer presented here are more informative than relative risks of any prostate cancer and more suitable to use for counseling men with a family history of prostate cancer.
  • Bratt, O, et al. (författare)
  • The Study of Active Monitoring in Sweden (SAMS): A randomized study comparing two different follow-up schedules for active surveillance of low-risk prostate cancer.
  • 2013
  • Ingår i: Scandinavian Journal of Urology. - 2168-1805 .- 2168-1813. ; 47:5, s. 347-55
  • Tidskriftsartikel (refereegranskat)abstract
    • Abstract Objective. Only a minority of patients with low-risk prostate cancer needs treatment, but the methods for optimal selection of patients for treatment are not established. This article describes the Study of Active Monitoring in Sweden (SAMS), which aims to improve those methods. Material and methods. SAMS is a prospective, multicentre study of active surveillance for low-risk prostate cancer. It consists of a randomized part comparing standard rebiopsy and follow-up with an extensive initial rebiopsy coupled with less intensive follow-up and no further scheduled biopsies (SAMS-FU), as well as an observational part (SAMS-ObsQoL). Quality of life is assessed with questionnaires and compared with patients receiving primary curative treatment. SAMS-FU is planned to randomize 500 patients and SAMS-ObsQoL to include at least 500 patients during 5 years. The primary endpoint is conversion to active treatment. The secondary endpoints include symptoms, distant metastases and mortality. All patients will be followed for 10--15 years. Results. Inclusion started in October 2011. In March 2013, 148 patients were included at 13 Swedish urological centres. Conclusions. It is hoped that the results of SAMS will contribute to fewer patients with indolent, low-risk prostate cancer receiving unnecessary treatment and more patients on active surveillance who need treatment receiving it when the disease is still curable. The less intensive investigational follow-up in the SAMS-FU trial would reduce the healthcare resources allocated to this large group of patients if it replaced the present standard schedule.
  • Bratt, Ola, et al. (författare)
  • Upper Limit of Cancer Extent on Biopsy Defining Very Low Risk Prostate Cancer.
  • 2015
  • Ingår i: BJU International. - Blackwell Science Ltd. - 1464-4096. ; 116:2, s. 213-219
  • Tidskriftsartikel (refereegranskat)abstract
    • To investigate how much Gleason pattern 3 cancer the prostate biopsy specimens may contain without an increased risk of undetected more aggressive cancer, compared with the risk for cancers fulfilling the National Comprehensive Cancer Network (NCCN) criteria for very low risk prostate cancer.
  • Carlsson, Sigrid, 1982-, et al. (författare)
  • Risk of suicide in men with low-risk prostate cancer
  • 2013
  • Ingår i: European journal of cancer (Oxford, England : 1990). - 1879-0852. ; 49:7
  • Tidskriftsartikel (refereegranskat)abstract
    • PURPOSE: Risk of suicide is increased among men with prostate cancer. We investigated this association among men with low-risk cancer, usually detected by prostate specific antigen (PSA)-testing. PATIENTS AND METHODS: Relative risk (RR) of suicide was calculated by use of Poisson regression analysis within the Prostate Cancer data Base Sweden (PCBaSe) 2.0, a nation-wide, population-based database, comparing 105,736 men diagnosed with prostate cancer between 1997-2009 to 528,658 matched prostate cancer-free men. RESULTS: During the first 6months after diagnosis, there were 38 suicides among men with prostate cancer; incidence rate 0.73 per 1000 person-years (PY) and 30 suicides in the comparison cohort; 0.11 per 1000PY, corresponding to a RR of suicide of 6.5 (95% confidence interval (CI) 4.0-10). Risk was highest among men with distant metastases, incidence rate 1.25 per 1000PY, RR 10 (95% CI 5.1-21) but risk was also increased for men with low-risk tumours, incidence rate difference 0.45 per 1000PY and RR 5.2 (95% CI 2.3-12) and across categories of socioeconomic status and comorbidity. Eighteen months after diagnosis, risk of suicide had decreased to 0.27 per 1000PY, RR 1.0 (95% CI 0.68-1.5) for low-risk prostate cancer but remained increased among men with metastases, 0.57 per 1000PY, RR 1.8 (95% CI 1.1-2.9). CONCLUSION: Although the increase in absolute risk of suicide was modest, our findings reflect the severe psychological stress that prostate cancer patients may experience after diagnosis. The increased risk of suicide observed in men with prostate cancer, including low-risk, calls for increased awareness.
Skapa referenser, mejla, bekava och länka
fritt online (114)
Typ av publikation
tidskriftsartikel (521)
annan publikation (9)
doktorsavhandling (8)
forskningsöversikt (6)
konferensbidrag (2)
recension (1)
visa fler...
visa färre...
Typ av innehåll
refereegranskat (501)
övrigt vetenskapligt (69)
populärvet., debatt m.m. (2)
Stattin, Pär, (538)
Garmo, Hans (103)
Hallmans, Göran (96)
Adolfsson, Jan (86)
Bratt, Ola (75)
Robinson, David, (71)
visa fler...
Holmberg, Lars, (67)
Kaaks, Rudolf (65)
Bergh, Anders, (62)
Häggström, Christel, (59)
Stocks, Tanja, (58)
Egevad, Lars (56)
Manjer, Jonas, (54)
Lambe, Mats (53)
Jonsson, Håkan, (51)
Ulmer, Hanno (50)
Van Hemelrijck, Miek ... (49)
Wiklund, Fredrik (48)
Loeb, Stacy, (47)
Grönberg, Henrik (47)
Riboli, Elio (45)
Nagel, Gabriele (45)
Key, Timothy J (43)
Engeland, Anders (42)
Tretli, Steinar (41)
Björge, Tone (41)
Concin, Hans (40)
Bill-Axelson, Anna, (39)
Wikström, Pernilla, (39)
Travis, Ruth C (38)
Trichopoulou, Antoni ... (36)
Selmer, Randi (36)
Folkvaljon, Yasin, (36)
Stattin, P (35)
Tumino, Rosario (34)
Allen, Naomi E. (34)
Johansson, Mattias (34)
Bueno-de-Mesquita, H ... (34)
Appleby, Paul N (33)
Adami, Hans Olov (32)
Xu, Jianfeng (32)
Khaw, Kay-Tee (30)
Johansson, Jan-Erik (30)
Rinaldi, Sabina (30)
Drevin, Linda, (30)
Overvad, Kim (29)
Boeing, Heiner (29)
Palli, Domenico (29)
Lukanova, Annekatrin (28)
Holmberg, Erik, (26)
visa färre...
Umeå universitet (337)
Uppsala universitet (121)
Lunds universitet (56)
Karolinska Institutet (37)
Göteborgs universitet (27)
Örebro universitet (8)
visa fler...
Linköpings universitet (3)
Chalmers tekniska högskola (2)
Högskolan Kristianstad (1)
visa färre...
Engelska (529)
Svenska (7)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (456)
Lantbruksvetenskap (6)
Naturvetenskap (3)
Samhällsvetenskap (1)


pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy